natgillin/translations-raw huggingface dataset:
At a mirabegron dose of 200 mg, the QTcI interval did not exceed 10 msec at any time point in males, while in females the upper bound of the one-sided 95% confidence interval did exceed 10 msec between 0.5-6 hours, with a maximum difference from placebo at 5 hours where the mean effect was 10.42 msec (upper bound of the one-sided 95% CI 13.44 msec).
U dozi od 200 mg mirabregona QTcI interval nije prelazio 10 msek u niti jednom trenutku kod muškaraca, dok je kod žena gornja granica jednostranog 95 % CI prelazila 10 msek između 0,5-6 sati, s maksimalnom razlikom u placebo skupini nakon 5 sati, dok je srednja vrijednost učinka bila 10,42 msek (gornja granica jednostranog
Mirabegron is a substrate for cytochrome P450 (CYP) 3A4, CYP2D6, butyrylcholinesterase, uridine diphospho-glucuronosyltransferases (UGT), the efflux transporter P-glycoprotein (P-gp) and the influx organic cation transporters (OCT) OCT1, OCT2, and OCT3.
Mirabegron je supstrat citokroma P450 (CYP) 3A4, CYP2D6, butirilholinesteraze, uridindifosfo-glukuronozil-transferaze
Rare side effects (may affect up to 1 in 1,000 people)
Rijetke nuspojave (mogu se pojaviti kod do 1 na 1000 ljudi)
Betmiga 25 mg prolonged release film-coated tablets are oval, brown film-coated tablets, debossed with the company logo and “325” on the same side.
Betmiga 25 mg tablete s produljenim oslobađanjem su ovalne, smeđe filmom obložene tablete, s utisnutim logom tvrtke i oznakom “325” s iste strane.
Oval, brown tablet, debossed with the company logo and “325” on the same side.
Ovalna, smeđa tableta, s utisnutim logom tvrtke i oznakom “325” s iste strane.
Steady state concentrations are achieved within 7 days of once daily dosing with mirabegron.
Koncentracije u stanju dinamičke ravnoteže postižu se unutar 7 dana primjenom
The table below reflects the adverse reactions observed with mirabegron in the three 12-week phase 3 double blind, placebo controlled studies.
Tablica u nastavku prikazuje nuspojave zabilježene tijekom primjene mirabegrona u 3 dvostruko slijepa, placebo kontrolirana ispitivanja faze III u trajanju od 12 tjedana.
The frequency of tachycardia was 1.2% in patients receiving Betmiga 50 mg. Tachycardia led to discontinuation in 0.1% patients receiving Betmiga 50 mg.
Učestalost tahikardije bila je 1,2% kod bolesnika koji su primali 50 mg lijeka Betmiga.
The pharmacokinetics of mirabegron are not influenced by race.
Rasa ne utječe na farmakokinetiku mirabegrona.
mesoridazine, haloperidol, and chlorpromazine; o anti-infectives such as pentamidine, moxifloxacin, erythromycin, and clarithromycin.
prokainamida, ibutilida, flekainida, dofetilida i amiodarona; o lijekovi koji se primjenjuju kod alergijskog rinitisa; o antipsihotici (lijekovi za duševne bolesti) poput tioridazina, mezoridazina, haloperidola i klorpromazina; o lijekovi protiv infekcija poput pentamidina, moksifloksacina, eritromicina i klaritromicina.
Most adverse reactions were mild to moderate in severity.
Većina nuspojava bila je po težini blaga do umjerena.
Efficacy in patients with or without prior OAB antimuscarinic therapy Efficacy was demonstrated in patients with and without prior OAB antimuscarinic therapy.
Djelotvornost kod bolesnika s ili bez ranije terapije OAB-a antimuskarinskim lijekovima
However, since patients with a known history of QT prolongation or patients who are taking medicinal products known to prolong the QT interval were not included in these studies, the effects of mirabegron in these patients is unknown.
Međutim, budući da bolesnici, kod kojih je bilo poznato da imaju produljenje QT intervala ili bolesnici koji su uzimali lijekove za koje je poznato da produljuju QT
Interval p-value † Least squares mean adjusted for baseline, gender and geographical region.
95%-tni interval pouzdanosti p-vrijednost † najmanji kvadrati srednje vrijednosti prilagođene za polaznu vrijednost, spol i geografsku regiju.
Betmiga 50 mg prolonged-release tablets Hypromellose 2910, 6 mPa.s Macrogol 8,000
Betmiga 50 mg tablete s produljenim oslobađanjem hipromeloza 2910, 6 mPa.s makrogol 8000 željezov oksid, žuti (E172)
Mirabegron has been administered to healthy volunteers at single doses up to 400 mg. At this dose, adverse events reported included palpitations (1 of 6 subjects) and increased pulse rate exceeding 100 beats per minute (bpm) (3 of 6 subjects).
U toj dozi prijavljene nuspojave uključivale su palpitacije (1 od 6 ispitanika) i ubrzanje pulsa preko 100 otkucaja u minuti (3 od 6 ispitanika).
† Least squares mean adjusted for baseline, gender, and study.
† najmanji kvadrati srednje vrijednosti prilagođeni za početnu vrijednost, spol i ispitivanje.
Multiple once daily dosing of mirabegron resulted in a 79% increase in Cmax and a 241% increase in AUC of a single dose of desipramine.
79%-tnim povećanjem Cmax i 241%-tnim povećanjem AUC nakon jednokratne doze dezipramina.
Talk to your doctor or pharmacist before taking Betmiga: - if you have trouble emptying your bladder or you have a weak urine stream or if you take other medicines for the treatment of overactive bladder such as anticholinergic medicines.
ako imate problema s pražnjenjem svog mjehura ili imate slabiji mlaz urina ili ako uzimate ostale lijekove za liječenje sindroma prekomjerno aktivnog mjehura kao što su antikolinergički lijekovi - ako imate problema s bubrezima ili jetrom.
Mirabegron is extensively distributed.
Distribucija mirabegrona je opsežna.
Betmiga is available in aluminium-aluminium blister in packs containing 10, 20, 30, 50, 60, 90, 100 or 200 tablets and in high density polyethylene (HDPE) bottles with silica gel desiccant and child-resistant closures containing 90 tablets.
60, 90, 100 ili 200 tableta i u bocama od polietilena visoke gustoće (HDPE) sa sredstvom za sušenje sa silikagelom i zatvaračem sigurnim za djecu koje sadrže 90 tableta.
Eyelid oedema
Edem kapaka
Mean volume voided (mL) per micturition (FAS) (Secondary)
Srednji volumen mokrenja (ml) po mikciji (FAS) (Sekundarni)
In the overall population of males and females, a 2-fold increase in dose from 50 mg to 100 mg mirabegron increased Cmax and AUCtau by approximately 2.9- and 2.6-fold, respectively, whereas a 4-fold increase in dose from 50 mg to 200 mg mirabegron increased Cmax and AUCtau by approximately 8.4- and 6.5-fold.
U sveukupnoj populaciji muškaraca i žena, udvostručavanjem doze s 50 mg na 100 mg mirabegrona njegova se Cmax i AUCtau povećavaju oko 2,9 odnosno 2,6 puta,
Mean number of micturitions per 24 hours (FAS)
Srednji broj mikcija tijekom 24 sata (FAS)
Mean number of urgency incontinence episodes per 24 hours (FAS-I) (Secondary)
Srednja vrijednost broja epizoda urgentne inkontinencije tijekom 24 sata (FAS-I) (Sekundarni)
Branch Belgique/Belgien Tél/Tel: +32 (0)2 5580710
Astellas Pharma B.V.Branch Belgique/Belgien Tél/Tel: +32 (0)2 5580710
In volunteers with severe renal impairment (eGFR-MDRD 15 to 29 mL/min/1.73 m2), mean Cmax and AUC values were 92% and 118% higher.
15 do 29 ml/min1/.73 m2), srednje vrijednosti Cmax i AUC bile su 92% odnosno 118% više.
Patients with bladder outlet obstruction and patients taking antimuscarinics medicinal products for OAB
Bolesnici koji su ranije primali antimuskarinske lijekove za OAB-a
Betmiga 25 mg prolonged-release tablets Each tablet contains 25 mg of mirabegron.
Betmiga 25 mg tablete s produljenim oslobađanjem Svaka tableta sadrži 25 mg mirabegrona.
The potential for inhibition of P-gp by mirabegron should be considered when Betmiga is combined with sensitive P-gp substrates e.g. dabigatran.
Betmiga kombinira s osjetljivim supstratima P-gp, npr. dabigatranom.
ALT increased *observed during post-marketing experience
*primijećene nakon stavljanja lijeka u promet
Eye disorders
Poremećaji očiju
The main findings in rabbit embryofetal development studies included malformations of the heart (dilated aorta, cardiomegaly) at systemic exposures 36-fold higher than observed at the MHRD.
(dilatirana aorta, kardiomegalija) nakon sustavnog izlaganja 36 puta većem od onog primjećenog kod
Mean number of micturitions per 24 hours (FAS) (Co-primary)
Srednji broj mikcija tijekom 24 sata (FAS) (Višestruki primarni)
In addition mirabegron showed efficacy in patients who previously discontinued OAB antimuscarinic therapy due to insufficient effect (see Table 4).
Nadalje, mirabegron je bio djelotvoran kod bolesnika koji su prethodno prekinuli terapiju
Effects on pulse rate and blood pressure in patients with OAB In OAB patients (mean age of 59 years) across three 12-week phase 3 double blind, placebo controlled studies receiving Betmiga 50 mg once daily, an increase in mean difference from placebo of approximately 1 bpm for pulse rate and approximately 1 mm Hg or less in systolic blood pressure/diastolic blood pressure (SBP/DBP) was observed.
Kod bolesnika s OAB-om (srednje dobi od 59 godina) ispitivanih tijekom 12 tjedana dvostruko slijepog, placebo kontroliranog ispitivanja faze 3, koji su primali 50 mg lijeka Betmiga jedanput na dan, zabilježen je porast srednje vrijednosti razlike u odnosu na placebo u brzini pulsa od oko
Mirabegron increased mean voided volume per micturition and decreased the frequency of non-voiding contractions, without affecting voiding pressure, or residual urine in rat models of bladder overactivity.
Mirabegron je na modelima hiperaktivnog mjehura štakora povećao srednju vrijednost volumena uriniranja po mikciji i smanjio učestalost kontrakcija bez uriniranja, bez djelovanja na tlak mokrenja ili rezidualni urin.
Headache* Dizziness*
Glavobolja* Omaglica*
Pharmacokinetic studies performed with radio-labelled mirabegron have shown that the parent compound and/or its metabolites are excreted in the milk of rats at levels that were approximately 1.7-fold higher than plasma levels at 4 hours post administration (see section 4.6).
Ispitivanja farmakokinetike provedena s radiološki obilježenim mirabegronom pokazala su da se ishodni spoj i/ili njegovi metaboliti izlučuju u mlijeko štakora dostižući razine koje su otprilike
Subjective improvement in health-related quality of life measurements In the three 12-week phase 3 double blind, placebo controlled studies, treatment of the symptoms of OAB with mirabegron once daily resulted in a statistically significant improvement over placebo on the following health-related quality of life measures: treatment satisfaction and symptom bother.
U 3 dvostruko slijepa, placebo kontrolirana ispitivanja faze 3 u trajanju od 12 tjedana, liječenje simptoma OAB-a primjenom mirabegrona jedanput na dan, rezultiralo je, u usporedbi s placebom,
Urticaria Rash
Urtikarija Osip
- Increased heart rate (tachycardia) - Infection of the structures that carry urine (urinary tract infections) - Nausea - Constipation - Headache - Diarrhoea - Dizziness
- Vaginalna infekcija - Probavne tegobe (dispepsija) - Infekcija želuca (gastritis)
Mean change from baseline† Mean difference from placebo† (95% CI) p-value
Srednja promjena od početne vrijednosti† Srednja razlika vrijednosti od placeba† (95% CI) p-vrijednost
The frequency of urinary tract infections was 2.9% in patients receiving Betmiga 50 mg. Urinary tract infections led to discontinuation in none of the patients receiving Betmiga 50 mg. Serious adverse reactions included atrial fibrillation (0.2%).
Učestalost infekcija urinarnog trakta bila je 2,9% kod bolesnika koji su primali 50 mg lijeka Betmiga.
Betmiga 25 mg prolonged-release tablets Betmiga 50 mg prolonged-release tablets
Betmiga 25 mg tablete s produljenim oslobađanjem Betmiga 50 mg tablete s produljenim oslobađanjem
Woman of childbearing potential
Žene reproduktivne dobi
In addition, the use of mirabegron in elderly patients is high according to the data from postmarketing exposure presented in the PSUR.
Osim toga, prema podacima o izloženosti nakon stavljanja lijeka u promet prikazanima u PSUR-u, mirabegron se često koristi u starijih bolesnika.
Betmiga 25 mg prolonged-release tablets Hypromellose 2910, 6 mPa.s Macrogol 8,000
Betmiga 25 mg tablete s produljenim oslobađanjem hipromeloza 2910, 6 mPa.s makrogol 8000 željezov oksid, žuti (E172) željezov oksid, crveni (E172)
Betmiga is used to treat the symptoms of an overactive bladder in adults such as: - suddenly needing to empty your bladder (called urgency) - having to empty your bladder more than usual (called increased urinary frequency) - not being able to control when to empty your bladder (called urgency incontinence)
- iznenadna potreba za pražnjenjem mokraćnog mjehura (nagon na mokrenje) - potreba za pražnjenjem mokraćnog mjehura češće nego li je to uobičajeno (povećana učestalost mokrenja)
o antipsychotic medicines (medicines for mental illness) such as thioridazine,
o lijekovi koji se primjenjuju kod poremećaja srčanog ritma, poput kinidina, sotalola,
Patients with prior OAB antimuscarinic therapy Mean number of incontinence episodes per 24 hours (FAS-I)
Placeb o Mirabegro n 50 mg Srednja vrijednost broja epizoda inkontinencije tijekom 24 sata (FAS-I) (Višestruki primarni)
Following single dose administration of 100 mg Betmiga in volunteers with mild hepatic impairment (Child-Pugh Class A), mean mirabegron Cmax and AUC were increased by 9% and 19% relative to volunteers with normal hepatic function.
(Child-Pugh stadij A), srednja vrijednost Cmax i AUC mirabegrona povećana je za 9% odnosno 19%, u usporedbi s dobrovoljcima s normalnom funkcijom jetre.
100 mg, the upper bound of the one-sided 95% confidence interval did not exceed 10 msec at any time point for the largest time-matched mean difference from placebo in the QTcI interval.
I kod muškaraca i kod žena na kojima je primjenjen mirabegron u dozama od 50 i 100 mg najveća razlika u QTcI intervalu nije bila veća od 10 msek (gornja granica jednostranog 95% CI) u bilo kojem trenutku mjerenja u usporedbi s placebo skupinom.
The most common adverse reactions reported for patients treated with Betmiga 50 mg during the three 12-week phase 3 double blind, placebo controlled studies are tachycardia and urinary tract infections.
dvostruko slijepa, placebo kontrolirana ispitivanja faze 3, u trajanju od 12 tjedana, bile su tahikardija i infekcije urinarnog trakta.
Adults (including elderly patients) The recommended dose is 50 mg once daily
Preporučena doza iznosi 50 mg jedanput na dan.
* Statistically significantly superior compared to placebo at the 0.05 level without multiplicity adjustment.
* Statistički značajno bolje u usporedbi s placebom na razini 0,05 bez prilagođavanja multipliciteta.
Teл.
MHRD.
Each tablet contains 25 mg of mirabegron.
Svaka tableta sadrži 25 mg mirabegrona.
Each tablet contains 50 mg of mirabegron.
Svaka tableta sadrži 50 mg mirabegrona.
Mean change from baseline† -0.92 Mean difference from placebo† -95% Confidence Interval
Srednja promjena od početne vrijednosti† Srednja razlika od placeba† 95%-tni interval pouzdanosti
Urinary retention in patients with bladder outlet obstruction (BOO) and in patients taking antimuscarinic medicinal products for the treatment of OAB has been reported in postmarketing experience in patients taking mirabegron.
Zabilježena je retencija urina u bolesnika s opstukcijom izlaznog dijela mokraćnog mjehura (BOO, engl. bladder outlet opstruction) i u bolesnika koji uzimaju antimuskarinske lijekove za liječenje
Blood pressure increased
Porast krvnog tlaka Porast GGT Porast AST Porast ALT
Tel: +421 2 4444 2157
Astellas Pharma s.r.o. Tel: +421 2 4444 2157
Common side effects (may affect up to 1 in 10 people)
Ostale nuspojave uključuju: Česte nuspojave (mogu se pojaviti kod do 1 na 10 ljudi)
Fertility
Pruritus
‡ Not statistically significantly superior compared to placebo at the 0.05 level with multiplicity adjustment.
‡ Nije statistički značajno bolje u usporedbi s placebom na razini 0,05 s prilagođavanjem multipliciteta.
Drug-drug interactions
Interakcije s drugim lijekovima
Betmiga 50 mg prolonged-release tablets
Betmiga 50 mg tablete s produljenim oslobađanjem
Betmiga 50 mg prolonged-release tablets mirabegron
Betmiga 50 mg tablete s produljenim oslobađanjem mirabegron
# Statistically significantly superior compared to placebo at the 0.05 level with multiplicity adjustment.
# Statistički značajno bolje u usporedbi s placebom na razini 0,05 s prilagođavanjem multipliciteta.
Betmiga 25 mg prolonged-release tablets mirabegron
Betmiga 25 mg tablete s produljenim oslobađanjem mirabegron
Each tablet contains 25 mg of mirabegron
Svaka tableta sadrži 25 mg mirabegrona
Betmiga 25 mg prolonged-release tablets
Betmiga 25 mg tablete s produljenim oslobađanjem
Each tablet contains 50 mg of mirabegron
Svaka tableta sadrži 50 mg mirabegrona
Lip oedema
Makularni osip
Astellas Pharma Kft. Tel.: +36 1 577 8200
Tel.: +36 1 577 8200
Package leaflet: Information for the patient Betmiga 25 mg prolonged-release tablets Betmiga 50 mg prolonged-release tablets mirabegron
Betmiga 25 mg tablete s produljenim oslobađanjem Betmiga 50 mg tablete s produljenim oslobađanjem mirabegron
Betmiga has not been studied in patients with end stage renal disease (GFR < 15 mL/min/1.73 m2 or patients requiring haemodialysis) and, therefore, it is not recommended for use in this patient population.
<15 ml/min/1,73 m2 ili bolesnicima koji zahtijevaju hemodijalizu) te se stoga ne preporučuje njegova primjena u toj populaciji bolesnika.
This medicinal product is not recommended for use in patients with severe renal impairment (GFR 15 to 29 mL/min/1.73 m2) concomitantly receiving strong CYP3A inhibitors (see section 4.5).
29 ml/min/1,73 m2) koji istodobno primaju snažne inhibitore CYP3A (vidjeti dio 4.5).
Mean number of incontinence episodes per 24 hours (FAS-I) (Co-primary)
Srednji broj epizoda inkontinencije tijekom 24 sata (FAS-I)
Busuttil Ltd. Tel: +356 21447184
Tel: +356 21447184
What you need to know before you take Betmiga Do not take Betmiga:
Nemojte uzimati Betmigu:
Astellas Pharma Co. Ltd. Tel: +353 (0)1 4671555
Astellas Pharma Ges.m.b.H. Tel.: +43 (0)1 8772668
Placebo
Betmiga
Gender No dose adjustment is necessary according to gender.
Dozu nije potrebno prilagođavati prema spolu bolesnika.
Nausea* Constipation* Diarrhoea*
- Zatvor - Glavobolja - Proljev - Omaglica
Apealea (paclitaxel)
Apealea (paklitaksel)
Further information on Apealea can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/apealea.
Više informacija o lijeku Apealea nalazi se na internetskim stranicama Agencije: ema.europa.eu/medicines/human/EPAR/apealea.
It belongs to the group of cancer medicines known as the ‘taxanes'.
On pripada skupini lijekova pod nazivom „taksani”.
The dose of Apealea is 250 mg per square metre (calculated based on height and body weight) and is given by infusion over about 1 hour, once every 3 weeks, for 6 cycles of treatment.
Doza lijeka Apealea iznosi 250 mg po kvadratnom metru (izračunana na temelju tjelesne visine i težine) i daje se infuzijom u trajanju od sat vremena, jedanput svaka tri tjedna u šest ciklusa terapije.
The average length of time that patients lived without their disease coming back yet again was 10.3 months with Apealea, and 10.1 months with conventional paclitaxel.
Prosječno vrijeme preživljenja bolesnica bez ponovnog pojavljivanja bolesti iznosilo je 10,3 mjeseca s lijekom Apealea i 10,1 mjesec s konvencionalnim paklitakselom.
The most common side effects with Apealea (which may affect more than 1 in 10 people) are neutropenia (low numbers of white blood cells called neutrophils), stomach and gut disorders such as diarrhoea, nausea (feeling sick) and vomiting, peripheral neuropathy (nerve damage in hands and feet), joint and muscle pain, and reactions such as redness, soreness and inflammation of the veins at the site of infusion.
Najčešće nuspojave lijeka Apealea (mogu se pojaviti u više od 1 na 10 bolesnika) su neutropenija (nizak broj bijelih krvnih stanica pod nazivom neutrofili), poremećaji želuca i crijeva kao što su proljev, mučnina (slabost) i povraćanje, periferna neuropatija (oštećenje živaca u rukama i stopalima), bol u zglobovima i mišićima i reakcije poput crvenila, boli i upale vena na mjestu infuzije.
The European Medicines Agency considered that Apealea was as effective as conventional paclitaxel, and could be a valuable alternative in combination with carboplatin.
Europska agencija za lijekove smatrala je da je Apealea jednako djelotvorna kao i konvencionalni paklitaksel te da se može smatrati dostojnom alternativom u kombinaciji s karboplatinom.
Other information about Apealea
Ostale informacije o lijeku Apealea
While the new formulation might be associated with more infusion site reactions, and studies suggested stronger effects on blood cells and the gut, these were considered manageable and the overall benefits and risks are consistent with those of other paclitaxel medicines.
Premda se nova formulacija može povezati s više reakcija na mjestu infuzije te ispitivanja pokazuju snažnije djelovanje na krvne stanice i crijeva, te se nuspojave mogu kontrolirati, a ukupne koristi i rizici u skladu su s koristima i rizicima drugih lijekova s paklitakselom.
Apealea (paclitaxel) EMA/791927/2018
Apealea (paklitaksel) EMA/653818/2018
For more information about using Apealea, see the package leaflet or contact your doctor or pharmacist.
Za više informacija o primjeni lijeka Apealea pogledajte uputu o lijeku ili se obratite liječniku ili ljekarniku.
The medicine can only be obtained with a prescription and should be given under the supervision of a specialist in the treatment of cancer.
Lijek se izdaje samo na liječnički recept, a liječenje se provodi pod nadzorom liječnika specijalista u liječenju raka.
What is Apealea and what is it used for?
Što je Apealea i za što se primjenjuje?
Supportive data from the study showed that the average time that patients lived after treatment was 25.7 months among those given Apealea and 24.8 months for those given conventional paclitaxel.
Potkrepljujući podatci iz ispitivanja pokazali su da je prosječno vrijeme preživljenja nakon liječenja iznosilo 25,7 mjeseci za bolesnice koje su primile lijek Apealea i 24,8 mjeseci za bolesnice koje su primile konvencionalni paklitaksel.
Apealea has been shown to be as effective as a conventional formulation of paclitaxel in one main study involving further treatment of 789 women whose ovarian, fallopian tube or peritoneal cancer had come back.
Lijek Apealea pokazao se jednako djelotvornim kao konvencionalna formulacija paklitaksela u jednom glavnom ispitivanju koje je obuhvaćalo daljnje liječenje 789 žena kod kojih su se vratili rak jajnika, jajovoda ili peritoneuma.
Side effects reported with Apealea are carefully evaluated and any necessary action taken to protect patients.
Nuspojave prijavljene za lijek Apealea pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
What measures are being taken to ensure the safe and effective use of Apealea?
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Apealea?
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Apealea have been included in the summary of product characteristics and the package leaflet.
Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Apealea nalaze se u sažetku opisa svojstava lijeka i u uputi o lijeku.
By keeping this structure intact the cells cannot divide and they eventually die.
Budući da struktura ostaje cjelovita, stanice se ne mogu dijeliti te naposljetku odumiru.
An overview of Apealea and why it is authorised in the EU
Pregled informacija o lijeku Apealea i zašto je odobren u EU-u
Apealea must not be used in patients who are breast feeding or those who already have low levels of neutrophils in the blood.
Apealea se ne smije primjenjivati u onih bolesnica koje doje ili u onih koje imaju nisku razinu neutrofila u krvi.
stage of cell division in which the cell's internal ‘skeleton' is dismantled to allow the cell to divide.
koje se unutarnji „kostur” stanice raspada kako bi se stanica mogla razdijeliti.